However, analysis of trial data from five long-acting GLP-1 agonists (exenatide once weekly, taspoglutide, albiglutide, LY2189265 and CJC-1134-PC) revealed that they were more likely than shorter-acting formulations to raise the heart rate (Robinson et al., 2013)
Your provider will slowly increase your dose over several months until you attain the maintenance dose
Reduced appetite and occasional injection-site reactions are also common
Four-Month Follow-Up: New Tools and Progress Blood pressure controlled OSA treated with CPAP game-changer for BP, insulin sensitivity, cortisol Mood and habits improved
Some women have reported flushing or hot sensations while taking tirzepatide, but this is quite rare and may coincide with natural menopause progression rather than being caused by the medication.
This is one of the reasons published Tirzepatide research is typically discussed not only in terms of efficacy, but also in terms of tolerability during escalation , GI event burden and the balance between metabolic benefit and dropout risk